Which best describes how lenalidomine and thalidomide function in the body?

Both drugs treat multiple myeloma by inhibiting inflammation, inhibiting formation of red blood cells, and modulating the immune system to kill cancer cells.
Both drugs treat leukemia by depriving the cancer cells of asparagine and preventing protein formation resulting in cellular death.
Both drugs treat breast cancer by blocking the aromatase enzyme necessary for estradiol production.
Both drugs treat lymphoma by aiding the immune system in identifying and binding to antigen proteins on the surface of cancer cells and triggering the cell to die.

Answer:

Multiple myeloma is a B-cell malignancy characterized by an excess of monotypic plasma cells in the bone marrow. The molecular mechanisms that are involved in disease progression depend on the interaction between the multiple myeloma cells and the bone microenvironment. Because these mechanisms have been well characterized, it is possible to develop regimens that are more specific to pathways involved in the pathogenesis of multiple myeloma than is typical for conventional chemotherapy in disease management. Thalidomide and immunomodulatory drugs (IMiDs) have now been shown to block several pathways important for disease progression in multiple myeloma. First established as agents with antiangiogenic properties, thalidomide and IMiDs inhibit the production of interleukin (IL)-6, which is a growth factor for the proliferation of myeloma cells. In addition, they activate apoptotic pathways through caspase 8-mediated cell death. At the mitochondrial level, they are responsible for c-jun terminal kinase (JNK)-dependent release of cytochrome-c and Smac into the cytosol of cells, where they regulate the activity of molecules that affect apoptosis. By activating T cells to produce IL-2, thalidomide and IMiDs alter natural killer (NK) cell numbers and function, thus augmenting the activity of NK-dependent cytotoxicity. Data delineating these events have been derived from experiments done in resistant and sensitive multiple myeloma cell lines. Although thalidomide and IMiDs demonstrate similar biologic activities, IMiDs are more potent than thalidomide and achieve responses at lower doses. Lenalidomide, a thalidomide derivative, has also been shown to have a different toxicity profile. Our understanding of the mechanism of action of these agents has provided a platform for exciting clinical trials evaluating combinations of thalidomide and lenalidomide with both conventional chemotherapy and newer targeted agents.

Explanation:

Shirya is at the dentist getting a cavity filled. The doctor injects her with a local anesthetic. Which drug did Shirya most likely receive?

lidocaine or procaine
methohexital or lorazepam
lorazepam or procaine
fentanyl or methohexital

what is the WHO formula for ORT​

“Diseases of the present age are very different from diseases of the past.

HCPCS level II codes are: a. sometimes replaced by HCPCS level III temporary codes. b. intended for use by all private and public health insurers. c. maintained by the AMA's Editorial Board, which makes decisions about additions, revisions, and deletions. d. updated by CMS when necessary, without participation by the HCPCS National Panel.

in the ear, the basilar membrane and hair cells are found in the?

Imagine that you are working with a team of bioarchaeologists that has just excavated a medieval cemetery site in Italy. The cemetery has over 200 graves, with all sexes and ages represented in the skeletal sample. You are interested in knowing whether there were gender differences in health among members of the medieval community. How would you answer this question using the skeletal remains

Should psychologists be asking about group differences (different race, sex, culture, etc.) in intellectual ability? What do you think?

If 3 grams of a drug are contained in 50 mL of solution, write the ratio.

How can health care professionals prepare for working with various age groups?